

Literaturverzeichnis

1. Ishii, I., et al., *Lysophospholipid receptors: signaling and biology*. Annu Rev Biochem, 2004. **73**: p. 321-54.
2. Brown, R.D., et al., *The cardiac fibroblast: therapeutic target in myocardial remodeling and failure*. Annu Rev Pharmacol Toxicol, 2005. **45**: p. 657-87.
3. Olivera, A., et al., *Sphingosine kinase type 1 induces G12/13-mediated stress fiber formation, yet promotes growth and survival independent of G protein-coupled receptors*. J Biol Chem, 2003. **278**(47): p. 46452-60.
4. Allende, M.L. and R.L. Proia, *Sphingosine-1-phosphate receptors and the development of the vascular system*. Biochim Biophys Acta, 2002. **1582**(1-3): p. 222-7.
5. Castillo, S.S. and D. Teegarden, *Sphingosine-1-phosphate inhibition of apoptosis requires mitogen-activated protein kinase phosphatase-1 in mouse fibroblast C3H10T 1/2 cells*. J Nutr, 2003. **133**(11): p. 3343-9.
6. Lee, H., E.J. Goetzl, and S. An, *Lysophosphatidic acid and sphingosine 1-phosphate stimulate endothelial cell wound healing*. Am J Physiol Cell Physiol, 2000. **278**(3): p. C612-8.
7. Karliner, J.S., *Lysophospholipids and the cardiovascular system*. Biochim Biophys Acta, 2002. **1582**(1-3): p. 216-21.
8. Panetti, T.S., *Differential effects of sphingosine 1-phosphate and lysophosphatidic acid on endothelial cells*. Biochim Biophys Acta, 2002. **1582**(1-3): p. 190-6.
9. Moolenaar, W.H., *Lysophosphatidic acid, a multifunctional phospholipid messenger*. J Biol Chem, 1995. **270**(22): p. 12949-52.
10. Zhang, C., et al., *Lysophosphatidic acid induces neointima formation through PPARgamma activation*. J Exp Med, 2004. **199**(6): p. 763-74.
11. Sauer, B., et al., *Lysophosphatidic acid interacts with transforming growth factor-beta signaling to mediate keratinocyte growth arrest and chemotaxis*. J Invest Dermatol, 2004. **123**(5): p. 840-9.
12. Chun, J., et al., *International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature*. Pharmacol Rev, 2002. **54**(2): p. 265-9.
13. Hu, Y.L., et al., *Dual mechanisms for lysophosphatidic acid stimulation of human ovarian carcinoma cells*. J Natl Cancer Inst, 2003. **95**(10): p. 733-40.

14. Nakajima, N., et al., *Expression and characterization of Edg-1 receptors in rat cardiomyocytes: calcium deregulation in response to sphingosine 1-phosphate*. Eur J Biochem, 2000. **267**(18): p. 5679-86.
15. Graler, M.H. and E.J. Goetzl, *The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors*. Faseb J, 2004. **18**(3): p. 551-3.
16. Weiner, J.A., et al., *Regulation of Schwann cell morphology and adhesion by receptor-mediated lysophosphatidic acid signaling*. J Neurosci, 2001. **21**(18): p. 7069-78.
17. Contos, J.J., et al., *Characterization of lpa(2) (Edg4) and lpa(1)/lpa(2) (Edg2/Edg4) lysophosphatidic acid receptor knockout mice: signaling deficits without obvious phenotypic abnormality attributable to lpa(2)*. Mol Cell Biol, 2002. **22**(19): p. 6921-9.
18. Gobeil, F., Jr., et al., *Modulation of pro-inflammatory gene expression by nuclear lysophosphatidic acid receptor type-1*. J Biol Chem, 2003. **278**(40): p. 38875-83.
19. Panetti, T.S., et al., *Modulation of cell interactions with extracellular matrix by lysophosphatidic acid and sphingosine 1-phosphate*. Prostaglandins, 2001. **64**(1-4): p. 93-106.
20. Sanchez, T. and T. Hla, *Structural and functional characteristics of SIP receptors*. J Cell Biochem, 2004. **92**(5): p. 913-22.
21. Mazurais, D., et al., *Cell type-specific localization of human cardiac SIP receptors*. J Histochem Cytochem, 2002. **50**(5): p. 661-70.
22. Van Brocklyn, J.R., et al., *Dual actions of sphingosine-1-phosphate: extracellular through the Gi-coupled receptor Edg-1 and intracellular to regulate proliferation and survival*. J Cell Biol, 1998. **142**(1): p. 229-40.
23. Kostenis, E., *Novel clusters of receptors for sphingosine-1-phosphate, sphingosylphosphorylcholine, and (lyso)-phosphatidic acid: new receptors for "old" ligands*. J Cell Biochem, 2004. **92**(5): p. 923-36.
24. Contos, J.J., I. Ishii, and J. Chun, *Lysophosphatidic acid receptors*. Mol Pharmacol, 2000. **58**(6): p. 1188-96.
25. Weber, K.T., *Cardiac interstitium in health and disease: the fibrillar collagen network*. J Am Coll Cardiol, 1989. **13**(7): p. 1637-52.
26. Zeydel, M., et al., *Properties of heart fibroblasts of adult rats in culture*. Cell Tissue Res, 1991. **265**(2): p. 353-9.
27. Manabe, I., T. Shindo, and R. Nagai, *Gene expression in fibroblasts and fibrosis: involvement in cardiac hypertrophy*. Circ Res, 2002. **91**(12): p. 1103-13.

28. Weber, K.T., *Fibrosis in hypertensive heart disease: focus on cardiac fibroblasts*. J Hypertens, 2004. **22**(1): p. 47-50.
29. Bishop, J.E. and G. Lindahl, *Regulation of cardiovascular collagen synthesis by mechanical load*. Cardiovasc Res, 1999. **42**(1): p. 27-44.
30. Bouzeghrane, F. and G. Thibault, *Is angiotensin II a proliferative factor of cardiac fibroblasts?* Cardiovasc Res, 2002. **53**(2): p. 304-12.
31. Olorundare, O.E., et al., *Assembly of a fibronectin matrix by adherent platelets stimulated by lysophosphatidic acid and other agonists*. Blood, 2001. **98**(1): p. 117-24.
32. Kupfahl, C., et al., *Angiotensin II directly increases transforming growth factor beta1 and osteopontin and indirectly affects collagen mRNA expression in the human heart*. Cardiovasc Res, 2000. **46**(3): p. 463-75.
33. Samuel, C.S., et al., *Relaxin modulates cardiac fibroblast proliferation, differentiation, and collagen production and reverses cardiac fibrosis in vivo*. Endocrinology, 2004. **145**(9): p. 4125-33.
34. Watanabe, T., et al., *17 beta-estradiol inhibits cardiac fibroblast growth through both subtypes of estrogen receptor*. Biochem Biophys Res Commun, 2003. **311**(2): p. 454-9.
35. Chen, M.M., et al., *CTGF expression is induced by TGF- beta in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis*. J Mol Cell Cardiol, 2000. **32**(10): p. 1805-19.
36. Kuwahara, F., et al., *Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats*. Circulation, 2002. **106**(1): p. 130-5.
37. Ahmed, M.S., et al., *Connective tissue growth factor--a novel mediator of angiotensin II-stimulated cardiac fibroblast activation in heart failure in rats*. J Mol Cell Cardiol, 2004. **36**(3): p. 393-404.
38. Duncan, M.R., et al., *Connective tissue growth factor mediates transforming growth factor beta-induced collagen synthesis: down-regulation by cAMP*. Faseb J, 1999. **13**(13): p. 1774-86.
39. Ohta, H., et al., *Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors*. Mol Pharmacol, 2003. **64**(4): p. 994-1005.
40. Yang, M., et al., *[Connective tissue growth factor synergistically with transforming growth factor beta 1 to promote renal fibrosis]*. Zhonghua Yi Xue Za Zhi, 2004. **84**(7): p. 569-73.

41. Zhou, G., C. Li, and L. Cai, *Advanced glycation end-products induce connective tissue growth factor-mediated renal fibrosis predominantly through transforming growth factor beta-independent pathway*. *Am J Pathol*, 2004. **165**(6): p. 2033-43.
42. Heusinger-Ribeiro, J., et al., *Expression of connective tissue growth factor in human renal fibroblasts: regulatory roles of RhoA and cAMP*. *J Am Soc Nephrol*, 2001. **12**(9): p. 1853-61.
43. Piazza, G.A., J.L. Ritter, and C.A. Baracka, *Lysophosphatidic acid induction of transforming growth factors alpha and beta: modulation of proliferation and differentiation in cultured human keratinocytes and mouse skin*. *Exp Cell Res*, 1995. **216**(1): p. 51-64.
44. Sato, M., et al., *Lysophosphatidic acid inhibits TGF-beta-mediated stimulation of type I collagen mRNA stability via an ERK-dependent pathway in dermal fibroblasts*. *Matrix Biol*, 2004. **23**(6): p. 353-61.
45. Fielitz, J., et al., *Regulation of matrix metalloproteinases and their inhibitors in the left ventricular myocardium of patients with aortic stenosis*. *J Mol Med*, 2004. **82**(12): p. 809-20.
46. Kassiri, Z. and R. Khokha, *Myocardial extra-cellular matrix and its regulation by metalloproteinases and their inhibitors*. *Thromb Haemost*, 2005. **93**(2): p. 212-9.
47. Fedak, P.W., et al., *Cardiac remodeling and failure From molecules to man (Part II)*. *Cardiovasc Pathol*, 2005. **14**(2): p. 49-60.
48. Hanafusa, N., et al., *Sphingosine 1-phosphate stimulates rat mesangial cell proliferation from outside the cells*. *Nephrol Dial Transplant*, 2002. **17**(4): p. 580-6.
49. Panichi, V., et al., *Effects of 1,25(OH)2D3 in experimental mesangial proliferative nephritis in rats*. *Kidney Int*, 2001. **60**(1): p. 87-95.
50. Katsuma, S., et al., *Signalling mechanisms in sphingosine 1-phosphate-promoted mesangial cell proliferation*. *Genes Cells*, 2002. **7**(12): p. 1217-30.
51. Jang, I.S., et al., *Altered cAMP signaling induced by lysophosphatidic acid in senescent human diploid fibroblasts*. *Biochem Biophys Res Commun*, 2003. **302**(4): p. 778-84.
52. Furui, T., et al., *Overexpression of edg-2/vzg-1 induces apoptosis and anoikis in ovarian cancer cells in a lysophosphatidic acid-independent manner*. *Clin Cancer Res*, 1999. **5**(12): p. 4308-18.
53. Breul, S.D., et al., *Control of collagen production by human diploid lung fibroblasts*. *J Biol Chem*, 1980. **255**(11): p. 5250-60.

54. Dawes, K.E., et al., *Changes in collagen metabolism in response to endothelin-1: evidence for fibroblast heterogeneity*. Int J Biochem Cell Biol, 1996. **28**(2): p. 229-38.
55. Fredriksson, K., et al., *Red blood cells inhibit proliferation and stimulate apoptosis in human lung fibroblasts in vitro*. Scand J Immunol, 2004. **59**(6): p. 559-65.
56. Peters, H., et al., *Selective lymphocyte inhibition by FTY720 slows the progressive course of chronic anti-thy 1 glomerulosclerosis*. Kidney Int, 2004. **66**(4): p. 1434-43.
57. Kramer, S., et al., *Mycophenolate mofetil slows progression in anti-thy1-induced chronic renal fibrosis but is not additive to a high dose of enalapril*. Am J Physiol Renal Physiol, 2005. **289**(2): p. F359-68.
58. Sawicka, E., et al., *Inhibition of Th1- and Th2-mediated airway inflammation by the sphingosine 1-phosphate receptor agonist FTY720*. J Immunol, 2003. **171**(11): p. 6206-14.
59. Brinkmann, V., *FTY720: mechanism of action and potential benefit in organ transplantation*. Yonsei Med J, 2004. **45**(6): p. 991-7.
60. Dragun, D., et al., *FTY720: early clinical experience*. Transplant Proc, 2004. **36**(2 Suppl): p. 544S-548S.
61. Denton, M.D., C.C. Magee, and M.H. Sayegh, *Immunosuppressive strategies in transplantation*. Lancet, 1999. **353**(9158): p. 1083-91.
62. Kappos, L., et al., *Oral fingolimod (FTY720) for relapsing multiple sclerosis*. N Engl J Med, 2006. **355**(11): p. 1124-40.
63. Brinkmann, V. and K.R. Lynch, *FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity*. Curr Opin Immunol, 2002. **14**(5): p. 569-75.
64. Mandala, S., et al., *Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists*. Science, 2002. **296**(5566): p. 346-9.
65. Wang, Y., et al., *Stimulation of soluble guanylate cyclase slows progression in anti-thy1-induced chronic glomerulosclerosis*. Kidney Int, 2005. **68**(1): p. 47-61.
66. Wang, Y., et al., *Enhancing cGMP in experimental progressive renal fibrosis: soluble guanylate cyclase stimulation vs. phosphodiesterase inhibition*. Am J Physiol Renal Physiol, 2006. **290**(1): p. F167-76.
67. Saiki, R.K., et al., *Analysis of enzymatically amplified beta-globin and HLA-DQ alpha DNA with allele-specific oligonucleotide probes*. Nature, 1986. **324**(6093): p. 163-6.
68. Kurien, B.T. and R.H. Scofield, *Protein blotting: a review*. J Immunol Methods, 2003. **274**(1-2): p. 1-15.

69. Eghbali, M., et al., *Cardiac fibroblasts are predisposed to convert into myocyte phenotype: specific effect of transforming growth factor beta*. Proc Natl Acad Sci U S A, 1991. **88**(3): p. 795-9.
70. Oliver, J.A., M.R. Goldberg, and Q. Al-Awqati, *Endothelial cell targeting during renal development: use of monoclonal antibodies*. Am J Physiol, 1997. **272**(2 Pt 2): p. F153-9.
71. Jost, L.M., J.M. Kirkwood, and T.L. Whiteside, *Improved short- and long-term XTT-based colorimetric cellular cytotoxicity assay for melanoma and other tumor cells*. J Immunol Methods, 1992. **147**(2): p. 153-65.
72. Batra, V., et al., *Bronchoalveolar lavage fluid concentrations of transforming growth factor (TGF)-beta1, TGF-beta2, interleukin (IL)-4 and IL-13 after segmental allergen challenge and their effects on alpha-smooth muscle actin and collagen III synthesis by primary human lung fibroblasts*. Clin Exp Allergy, 2004. **34**(3): p. 437-44.
73. Cleutjens, J.P., *The role of matrix metalloproteinases in heart disease*. Cardiovasc Res, 1996. **32**(5): p. 816-21.
74. Sengupta, S., et al., *Lysophosphatidic acid downregulates tissue inhibitor of metalloproteinases, which are negatively involved in lysophosphatidic acid-induced cell invasion*. Oncogene, 2006.
75. Villarreal, F.J. and W.H. Dillmann, *Cardiac hypertrophy-induced changes in mRNA levels for TGF-beta 1, fibronectin, and collagen*. Am J Physiol, 1992. **262**(6 Pt 2): p. H1861-6.
76. Zhang, Q., et al., *Modulation of cell surface fibronectin assembly sites by lysophosphatidic acid*. J Cell Biol, 1994. **127**(5): p. 1447-59.
77. Tsuruda, T., L.C. Costello-Boerrigter, and J.C. Burnett, Jr., *Matrix metalloproteinases: pathways of induction by bioactive molecules*. Heart Fail Rev, 2004. **9**(1): p. 53-61.
78. Burlew, B.S. and K.T. Weber, *Cardiac fibrosis as a cause of diastolic dysfunction*. Herz, 2002. **27**(2): p. 92-8.
79. Nicoletti, A. and J.B. Michel, *Cardiac fibrosis and inflammation: interaction with hemodynamic and hormonal factors*. Cardiovasc Res, 1999. **41**(3): p. 532-43.
80. Parkin, J. and B. Cohen, *An overview of the immune system*. Lancet, 2001. **357**(9270): p. 1777-89.
81. Cremers, B., et al., *Modulation of myocardial contractility by lysophosphatidic acid (LPA)*. J Mol Cell Cardiol, 2003. **35**(1): p. 71-80.

82. Xin, C., et al., *The immunomodulator FTY720 and its phosphorylated derivative activate the Smad signalling cascade and upregulate connective tissue growth factor and collagen type IV expression in renal mesangial cells*. Br J Pharmacol, 2006. **147**(2): p. 164-74.
83. Xin, C., et al., *Sphingosine 1-phosphate cross-activates the Smad signaling cascade and mimics transforming growth factor-beta-induced cell responses*. J Biol Chem, 2004. **279**(34): p. 35255-62.